Figure 2
MRD quantification by RQ-PCR of 190 patients before, during, and after induction. MRD levels at diagnosis, at midterm staging, and after induction are given. Combined immunochemotherapy resulted in a reduction of lymphoma cells of 3 orders of magnitude in peripheral blood (PB) and bone marrow (BM) from 6.2 × 10−2 in PB and 7.0 × 10−2 in BM prior treatment to 1.0 × 10−4 in PB and 1.2 × 10−4 in BM at midterm staging (P < .001) and the median of samples were MRD negative after end of induction (before DexaBEAM/autologous stem cell transplantation or maintenance). Black lines indicate the median MRD level at the stated time point.
